US Drug Recall Register
Class II · Moderate risk Terminated Initiated Sep 26, 2017 (9 years ago)

Alprazolam Tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed Impurities/Degradation Specifications: Out-of-specification result for an unknown impurity.

What was recalled

Alprazolam Tablets, USP, 0.25 mg, 100-count Unit Dose tablets per carton, Rx Only, Manufactured by: Watson Pharma Private Limited, Verna, Salcette Goa 403 722 INDIA; Distributed by: Actavis Pharma, Inc., Parsippany, NJ 07054; Distributed by: Major Pharmaceuticals, 17177 N. Laurel Park Dr., Suite 233, Livonia, MI 48152, NDC 0904-5858-61.

Recalling firm
The Harvard Drug Group
NDC code
0904-5858-61
Origin
MI, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0013-2018

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Alprazolam recalls

See all
Class II · Moderate risk Ongoing

Xanax XR

Reason Failed Dissolution Specifications

Viatris, Inc. NDC 58151-506-91 D-0444-2026
Class II · Moderate risk Terminated

Alprazolam Tab

Reason CGMP Deviations: Downstream recall from Breckenridge Pharmaceuticals, Inc due to potential risk of Cross Contamination.

Preferred Pharmaceuticals, Inc. NDC 68788-7596-3 D-0506-2023
Class II · Moderate risk Terminated

Alprazolam Tab

Reason CGMP Deviations: Downstream recall from Breckenridge Pharmaceuticals, Inc due to potential risk of Cross Contamination.

Preferred Pharmaceuticals, Inc. NDC 68788-7595-3 D-0505-2023
Class II · Moderate risk Terminated

Alprazolam Tab

Reason CGMP Deviations: Downstream recall from Breckenridge Pharmaceuticals, Inc due to potential risk of Cross Contamination.

Preferred Pharmaceuticals, Inc. NDC 68788-7594-3 D-0504-2023
Class II · Moderate risk Ongoing

Alprazolam C-IV

Reason CGMP Deviations: Repackaging firm recalling due to potential product cross contamination concerns at the manufacturer.

Direct Rx NDC 72189-121-60 D-0509-2023